In light of the fact that IL-2 activated NK cells have been demonstrated to specifically lyse not only CML cell lines but also primary blasts [48], and the observation that activated NK cells home into the bone marrow [49], the therapeutic possibilities of this cell population have attracted much investigation in CML. The gene discussed is IL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.